Effect of chronic Sildenafil treatment on the prostate of C57Bl/6 mice

dc.creatorGomes, Fabiana Oliveira dos Santos
dc.creatorCarvalho, Maria da Conceição
dc.creatorSaraiva, Karina Lidianne Alcântara
dc.creatorRibeiro, Edlene Lima
dc.creatorSoares e Silva, Amanda Karolina
dc.creatorDonato, Mariana Aragão Matos
dc.creatorRocha, Sura Wanessa Santos
dc.creatorSantos e Silva, Bruna
dc.creatorPeixoto, Christina Alves
dc.creatorPróstata, efeitos de drogas
dc.date2017-11-20T13:13:22Z
dc.date2017-11-20T13:13:22Z
dc.date2014
dc.date.accessioned2023-09-26T22:24:26Z
dc.date.available2023-09-26T22:24:26Z
dc.identifierGOMES, F. O. DOS S. et al. Effect of chronic Sildenafil treatment on the prostate of C57Bl/6 mice. Tissue & Cell, v. 46, n. 6, p. 439–449, dez. 2014.
dc.identifier1532-3072
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/23269
dc.identifier10.1016/j.tice.2014.08.001
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8878858
dc.descriptionSildenafil is a potent and selective inhibitor of phosphodiesterase-5 (PDE5) and is considered first-line therapy for erectile dysfunction. Nowadays, Sildenafil is used extensively throughout the world on patients with pulmonary hypertension. However, few studies have evaluated the possible side effects of chronic Sildenafil treatment on the male reproductive system, specifically in the prostate. In the present study, it was demonstrated via morphological and ultrastructural analysis that chronic treatment with Sildenafil induced an enhancement of the glandular activity of the prostate. In addition, mice treated with Sildenafil showed a significant increase in testosterone serum levels. However, no statistically significant differences were observed in nitric oxide serum levels, or in sGC, eNOS, PSA and TGF-β prostatic expression. In conclusion, the present study suggests that chronic use of Sildenafil does not cause evident prostatic damage, and therefore, can be used pharmacologically to treat a variety of disorders.
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier
dc.rightsopen access
dc.subjectSildenafila
dc.subjectInibidor da Nucleotídeo Cíclico Fosfodiesterase do Tipo 5
dc.subjectPróstata
dc.subjectSildenafil
dc.subjectInhibitor of phosphodiesterase-5 (PDE5)
dc.subjectProstate
dc.subjectDisfunção Erétil
dc.subjecttratamento farmacológico
dc.subjectPiperazinas
dc.subjectadministração & dosagem
dc.subjectPróstata
dc.subjectultraestrutura
dc.subjectulfonamidas
dc.subjectadministração & dosagem
dc.subjectAnimais
dc.subjectHumanos
dc.subjectDisfunção Erétil
dc.subjectsangue
dc.subjectDisfunção Erétil
dc.subjectpatologia
dc.subjectHipertensão Pulmonar
dc.subjecttratamento farmacológico
dc.subjectMasculino
dc.subjectCamundongos Endogâmicos C57BL
dc.subjectÓxido Nítrico Sintase Tipo III
dc.subjectsangue
dc.subjectAntígeno Prostático Específico
dc.subjectsangue
dc.subjectPurinas
dc.subjectadministração & dosagem
dc.subjectTestosterona
dc.subjectsangue
dc.subjectFator de Crescimento Transformador beta
dc.subjectsangue
dc.subjectCitrato de Sildenafila
dc.titleEffect of chronic Sildenafil treatment on the prostate of C57Bl/6 mice
dc.typeArticle


Este ítem pertenece a la siguiente institución